A share price of Bicycle Therapeutics Plc ADR [BCYC] is currently trading at $7.31, up 6.40%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BCYC shares have gain 16.96% over the last week, with a monthly amount drifted -11.07%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bicycle Therapeutics Plc ADR [NASDAQ: BCYC] stock has seen the most recent analyst activity on November 24, 2025, when Truist initiated its Hold rating and assigned the stock a price target of $19. Previously, RBC Capital Mkts downgraded its rating to Sector Perform on October 31, 2025, and kept the price target unchanged to $11. On November 08, 2024, Stephens initiated with a Equal-Weight rating and assigned a price target of $25 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $35 on September 06, 2024. B. Riley Securities downgraded its rating to a Neutral and reduced its price target to $28 on August 07, 2024. B. Riley Securities upgraded its rating to Buy for this stock on September 11, 2023. In a note dated August 31, 2022, Cowen initiated an Outperform rating.
Bicycle Therapeutics Plc ADR experienced fluctuations in its stock price throughout the past year between $6.03 and $21.50. Currently, Wall Street analysts expect the stock to reach $11 within the next 12 months. Bicycle Therapeutics Plc ADR [NASDAQ: BCYC] shares were valued at $7.31 at the most recent close of the market. An investor can expect a potential return of 50.48% based on the average BCYC price forecast.
Analyzing the BCYC fundamentals
Trailing Twelve Months sales for Bicycle Therapeutics Plc ADR [NASDAQ:BCYC] were 28.31M which represents 331.43% growth. Gross Profit Margin for this corporation currently stands at -5.92% with Operating Profit Margin at -10.23%, Pretax Profit Margin comes in at -8.92%, and Net Profit Margin reading is -8.85%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.36 and Total Capital is -0.42. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.93 points at the first support level, and at 6.54 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.53, and for the 2nd resistance point, it is at 7.74.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Bicycle Therapeutics Plc ADR [NASDAQ:BCYC] is 10.66. As well, the Quick Ratio is 10.66, while the Cash Ratio is 9.36. Considering the valuation of this stock, the price to sales ratio is 12.88, the price to book ratio is 0.82.
Transactions by insiders
Recent insider trading involved Lee Kevin, CHIEF EXECUTIVE OFFICER, that happened on Oct 03 ’25 when 3231.0 shares were sold. CHIEF EXECUTIVE OFFICER, Lee Kevin completed a deal on Oct 02 ’25 to sell 2263.0 shares. Meanwhile, CHIEF TECHNOLOGY OFFICER Skynner Michael sold 978.0 shares on Oct 03 ’25.
